October 22, 2021 10:39 AM EDTUpdated October 25, 06:33 AM
FDA+
Coronavirus

FDA says ben­e­fits of Covid-19 vac­cine for younger chil­dren out­weigh risks

Zachary Brennan

Senior Editor

The FDA said in its analy­sis of Pfiz­er’s da­ta that the ben­e­fits of the 2-dose pri­ma­ry se­ries in chil­dren 5-11 years of age out­weigh the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times